论文部分内容阅读
利拉鲁肽作为长效人胰升血糖素样肽-1(GLP-1)类似物,具有葡萄糖浓度依赖性的降糖效应和改善β细胞功能、减重、降压、降脂等多种降糖外效应。大型临床三期LEAD试验研究证实,利拉鲁肽无论是单独使用还是联合用药,除具良好的降糖效应外,还可减少低血糖事件的发生,发挥全面的心血管保护作用,其疗效无年龄依赖性,总体耐受性好,治疗过程中抗体滴度低,且目前尚无确切证据表明利拉鲁肽与急性胰腺炎和甲状腺C细胞癌相关。利拉鲁肽良好的疗效和安全性,为2型糖尿病患者提供了新的治疗方案。
Liraglutide, as a long-acting human glucagon-like peptide-1 (GLP-1) analogue, has a glucose-concentration-dependent hypoglycemic effect and is capable of improving β-cell function, reducing weight, lowering blood pressure, External hypoglycemic effect. Large clinical Phase III LEAD trial confirmed that liraglutide alone or in combination with drugs, in addition to a good hypoglycemic effect, but also reduce the incidence of hypoglycemic events, to play a comprehensive cardiovascular protection, the efficacy of no Age dependence, overall tolerability, and low antibody titers during treatment, and there is no conclusive evidence that liraglutide is associated with acute pancreatitis and thyroid C-cell carcinoma. The good efficacy and safety of liraglutide provides new treatment options for patients with type 2 diabetes.